stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) EPS (diluted)
NewAmsterdam Pharma Company N.V.'s EPS (diluted) for fiscal 2025 was −$1.72, compared with −$2.56 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.69. Over the past ten years it has ranged from −$2.56 (fiscal 2024) to $1.21 (fiscal 2021); the current reading is higher than 43% of that period. NewAmsterdam Pharma Company N.V. ranks 293rd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.72 | — |
| FY2024 | −$2.56 | — |
| FY2023 | −$2.15 | — |
| FY2022 | −$1.19 | — |
| FY2021 | $1.21 | 9,993.33% |
| FY2020 | $0.01 | — |
| FY2020 | $0.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.14 | — |
| Jun 2026 | −$0.52 | — |
| Mar 2026 | −$0.40 | — |
| Dec 2025 | −$0.63 | — |
| 21 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ADMA ADMA Biologics Inc compare | $0.77 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| NAMS NewAmsterdam Pharma Company N.V. | −$1.69 |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$1.71 |
| XNCR Xencor, Inc. compare | −$2.17 |
| MBX MBX Biosciences, Inc. compare | −$2.41 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NAMS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement